Please ensure Javascript is enabled for purposes of website accessibility

Abbott Labs Soars After Pandemic Buying Boosts Results

By Jim Crumly - Apr 16, 2020 at 2:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Consumers stock up as Abbott launches three COVID-19 tests.

Stay-at-home orders prompted consumers to stock up on nutrition products and customers in emerging markets were strong buyers of pharmaceuticals, helping Abbott Laboratories (ABT 3.05%) beat expectations for first-quarter results. Analyst estimates had been lowered drastically since the breakout of the COVID-19 pandemic in anticipation of a slowdown in routine medical procedures.

Sales increased 4.3% on an organic basis to $7.7 billion and adjusted earnings per share rose 3.2% to $0.65. Abbott had originally guided to EPS between $0.69 and $0.71 for the quarter, but analysts lowered estimates in the last month to $0.58 on expectations of significantly lower sales of medical devices and diagnostics as hospitals canceled routine procedures.

Lab technician putting samples in test tubes.

Image source: Getty Images.

Medical device sales still managed 2.9% organic growth year over year, and the diagnostics segment eked out a sales gain of 0.7%. Sales of nutrition products rose 7.3%, driven by buying of pediatric nutrition products in the U.S. in advance of shelter-in-place restrictions. Established pharmaceuticals sales rose 9.3% organically.

Abbott withdrew guidance for the full year, which previously called for organic sales growth between 7% and 8%. But its diagnostic segment should get a boost from three new COVID-19 tests that the company has recently launched. One molecular test runs on Abbott's devices in hospitals and reference laboratories, while the other new molecular test produces results in as little as five minutes, and CVS Health is setting up drive-up stations in its parking lots to utilize the innovative system. The third test is an antibody test Abbott announced yesterday that will detect if a person has previously been infected with the SARS-CoV-2 virus. The company expects to ship 4 million antibody tests in April, ramping up to 20 million in June.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$109.45 (3.05%) $3.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.